The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first drug approved in the EU to specifically target the underlying progression of disability in SPMS patients without recent relapses. Cenrifki works by inhibiting brain-penetrant Bruton tyrosine kinase to reduce neuroinflammation, a key factor in SPMS progression. Sanofi plans to launch Cenrifki commercially in Germany this year, with close medical oversight and risk management to ensure patient safety, especially monitoring liver enzyme elevations linked to the drug.
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...
Sanofi has named Paulo Fontoura as its new Executive Vice President and Global Head of Research & Development Pharma, effective September 1, 2026. Fontoura brings over 25 years of experience in medicine and pharmaceutical innovation, having held seni...
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
Japan's Ministry of Health has approved Sanofi's Sarclisa subcutaneous (SC) formulation for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval is based on the IRAKLIA phase 3 study showing the SC form is...
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...
